Insider trade

Officer sold ~$221K of DXCM shares in the open market

Traded Sep 28, 2026 · Filed Sep 30, 2026

DexcomDXCM

~$221K
Reported value · 2,565 sh @ $86.15: 123K
Holds after · shares reported: -0.5%
stock since the trade · S&P 500 -0.2%, $86.68 → $86.23 on Oct 1

Why it stands out

Dexcom's Chief People & Culture Off sold $221K of Dexcom shares. It was planned long ago, so it says very little.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Sep 28, 2026
Reporting period: Not applicable
Filed with the SEC: Sep 30, 2026

Officer$100K–$500KPre-arranged plan referenced

Context

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$220,975

Shares × reported transaction price

Timing vs results

60 days after results of Jul 30, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $86.68 on Sep 28, 2026, 58% above its 52-week low and 6% below its high, after a 3% drop over the previous 30 trading days

52-week range $54.84 (Nov 10, 2025) to $92.34 (Aug 21, 2026), 85% of the way up, from 251 adjusted closes. 30 trading days earlier: $89.75 on Aug 14, 2026. Describes the past only, not a forecast

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

Securities lawsuit open at the trade date

A securities lawsuit naming the company as a defendant was filed on Oct 27, 2025 in the U.S. District Court, S.D. New York. A filing is an allegation, not a finding.

3 such cases were open. Prime v. DexCom, Inc., docket 1:25-cv-08912, via CourtListener (court records). Nature of suit 850, company named as first defendant

Source receipt

Record ID: 0001093557-26-000181
Filed / recorded: Sep 30, 2026, 8:15 PM UTC
Added to OQRO: Oct 2, 2026, 12:27 PM UTC
Parser: form4-xml-v1
Data quality: Verified: identifiers matched exactly
Issuer: DEXCOM INC
Issuer CIK: 1093557
Ticker: DXCM
Reporting person: Sadie Stern
Relationship: Officer
Officer title: EVP Chief People & Culture Off
Security: Common Stock
Table: Non-derivative (Table I)
Transaction date: Sep 28, 2026
Transaction code: S
Shares / units: 2,565
Price per share: $86.15
Acquired / disposed: Disposed (D)
Shares owned after: 123,478
Ownership form: Direct
Amendment: No

Footnotes from the filing

On May 28, 2026, Ms. Stern adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Stern. The shares set forth above were sold pursuant to the 10b5-1 Plan.
Included in this number are 71,903 unvested restricted stock units, 39,019 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 19,948 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 5,699 of which were granted on March 8, 2025 and shall vest through March 8, 2027, and 7,237 of which were granted on March 8, 2024 and shall vest through March 8, 2027.

Around the same time

Officer plans to sell ~$221K of Dexcom

Planned, from pay7d ago

Director sold ~$130K of Dexcom

Scheduled in advance3w ago

Director sold ~$550K of Dexcom